| Data-based analysis, modelling and forecasting of the COVID-19 outbreak C Anastassopoulou, L Russo, A Tsakris, C Siettos PloS one 15 (3), e0230405, 2020 | 1083 | 2020 |
| Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity C Anastassopoulou, Z Gkizarioti, GP Patrinos, A Tsakris Human genomics 14 (1), 40, 2020 | 182 | 2020 |
| Effect of recent thymic emigrants on progression of HIV-1 disease A Hatzakis, G Touloumi, R Karanicolas, A Karafoulidou, T Mandalaki, ... The Lancet 355 (9204), 599-604, 2000 | 134 | 2000 |
| Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 CG Anastassopoulou, TJ Ketas, PJ Klasse, JP Moore Proceedings of the National Academy of Sciences 106 (13), 5318-5323, 2009 | 116 | 2009 |
| Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA … LG Kostrikis, G Touloumi, R Karanicolas, N Pantazis, C Anastassopoulou, ... Journal of virology 76 (20), 10099-10108, 2002 | 108 | 2002 |
| Tracing day-zero and forecasting the COVID-19 outbreak in Lombardy, Italy: A compartmental modelling and numerical optimization approach L Russo, C Anastassopoulou, A Tsakris, GN Bifulco, EF Campana, ... Plos one 15 (10), e0240649, 2020 | 92* | 2020 |
| A comparison of hepatitis B seroepidemiology in ten European countries A Nardone, CG Anastassopoulou, H Theeten, B Kriz, I Davidkin, ... Epidemiology & Infection 137 (7), 961-969, 2009 | 83 | 2009 |
| Modeling the 2014 ebola virus epidemic–agent-based simulations, temporal analysis and future predictions for liberia and sierra leone C Siettos, C Anastassopoulou, L Russo, C Grigoras, E Mylonakis PLoS currents 7, 2015 | 77 | 2015 |
| Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study S Medić, C Anastassopoulou, Z Lozanov-Crvenković, V Vuković, ... The Lancet Regional Health–Europe 20, 2022 | 71 | 2022 |
| Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss CG Anastassopoulou, AJ Marozsan, A Matet, AD Snyder, EJ Arts, ... PLoS pathogens 3 (6), e79, 2007 | 68 | 2007 |
| Low-dose IFN-α monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication A Hatzakis, P Gargalianos, V Kiosses, M Lazanas, V Sypsa, ... Journal of Interferon & Cytokine Research 21 (10), 861-869, 2001 | 67 | 2001 |
| Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy AE Hatzakis, G Touloumi, N Pantazis, CG Anastassopoulou, O Katsarou, ... Aids 18 (17), 2261-2267, 2004 | 63 | 2004 |
| Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines HC Maltezou, C Anastassopoulou, S Hatziantoniou, GA Poland, A Tsakris Vaccine 40 (2), 183-186, 2022 | 58 | 2022 |
| European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus F de Ory, JM Echevarría, G Kafatos, C Anastassopoulou, N Andrews, ... Journal of clinical virology 36 (2), 111-118, 2006 | 53 | 2006 |
| Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current … A Katsoulidou, M Petrodaskalaki, V Sypsa, E Papachristou, ... Journal of virological methods 131 (2), 168-174, 2006 | 46 | 2006 |
| Comparative hepatitis A seroepidemiology in 10 European countries S Kurkela, R Pebody, G Kafatos, N Andrews, C Barbara, B Bruzzone, ... Epidemiology & Infection 140 (12), 2172-2181, 2012 | 44 | 2012 |
| Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study S Hatziantoniou, HC Maltezou, A Tsakris, GA Poland, C Anastassopoulou Vaccine 39 (19), 2605, 2021 | 43 | 2021 |
| The impact of human allelic variation on HIV-1 disease CG Anastassopoulou, LG Kostrikis Current HIV research 1 (2), 185-203, 2003 | 43 | 2003 |
| Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users CG Anastassopoulou, D Paraskevis, V Sypsa, M Psichogiou, ... Journal of medical virology 56 (3), 246-252, 1998 | 43 | 1998 |
| Caenorhabditis elegans-based model systems for antifungal drug discovery C G Anastassopoulou, B Burgwyn Fuchs, E Mylonakis Current pharmaceutical design 17 (13), 1225-1233, 2011 | 39 | 2011 |
Athanasios Tsakris, Athanassios TsakrisNational and Kapodistrian University of Athens, Medical Schoolmed.uoa.gr üzerinde doğrulanmış e-posta adresine sahip
